NeOnc Technologies Holdings has reported positive Phase 2a results for intranasal NEO100 in recurrent or progressive IDH1-mutant high-grade glioma, with the experimental brain cancer therapy meeting its primary six-month progression-free survival endpoint. Six-month progression-free survival reached 48.9% by RANO 2.0 criteria compared with the study’s prespecified 20% historical benchmark, producing a p-value of 0.0047. Median overall survival was 26.09 months, while five of the 24 treated patients remained on therapy at the data cutoff. The findings give NeOnc Technologies Holdings a basis for requesting a Type B meeting with the United States Food and Drug Administration to discuss a potential registrational pathway, but the single-arm study remains too small and uncontrolled to establish how NEO100 would perform against contemporary treatment in a randomized population.
The readout is particularly relevant because the trial enrolled a difficult-to-treat population with Grade III or Grade IV IDH1-mutant tumors that had already progressed after radiation or combined temozolomide and radiation. NeOnc Technologies Holdings is positioning NEO100 differently from approved IDH-directed approaches developed primarily for earlier-stage, lower-grade glioma, arguing that patients with recurrent high-grade disease continue to lack an approved targeted therapy specifically for their setting.
A 48.9% six-month progression-free survival rate clears the study benchmark but not the randomized-trial hurdle
The Phase 2a portion of NEO100-01 evaluated 24 patients at a recommended dose of 1,152 milligrams per day. Patients self-administered NEO100 intranasally four times daily in 28-day treatment cycles until progression, death or withdrawal. All magnetic resonance imaging scans were assessed by an independent central reviewer, while efficacy was analyzed in the intent-to-treat population using RANO 2.0 response criteria.
The primary analysis estimated six-month progression-free survival at 48.9%, with a 95% confidence interval ranging from 26.3% to 68.1%. That substantially exceeded the prespecified 20% benchmark used as the expected standard-of-care performance and generated the statistically significant primary result.
The wide confidence interval highlights the uncertainty created by the small sample. With only 24 patients, a relatively small number of additional progressions could materially change the apparent rate, while historical comparisons are inherently less reliable than a concurrently randomized control group.
NeOnc Technologies Holdings itself acknowledged these limitations in its disclosure. The company noted that the study was open label, single arm and not powered as a confirmatory trial, and that historical comparisons can be affected by differences in patient characteristics, treatment era and response-assessment methods. The company also disclosed that the study included 24 patients despite an originally planned enrollment of 28.
These qualifications are important because the result should be interpreted as a strong Phase 2 signal rather than definitive evidence of superiority over existing care. The FDA meeting will help determine whether regulators believe the survival pattern is sufficiently persuasive to justify an efficient registrational program or whether a conventional randomized study will be required.
Median survival of 26.09 months adds durability to the NEO100 signal despite a low response rate
Overall survival provides additional context for the primary endpoint. Median overall survival reached 26.09 months, with 86.7% of patients alive at six months, 60.9% alive at 12 months and 54.1% alive at 24 months. Twelve of the 24 participants had died at the analysis cutoff.
The objective response rate was comparatively modest at 8.3%, representing two of 24 patients. Five patients nevertheless remained on active treatment, including one participant who had remained progression free for approximately 19 months and another whose partial response had persisted for at least 114 days through the end of the eighth treatment cycle.
That pattern suggests the potential value of NEO100 may depend more on durable disease control than dramatic tumor shrinkage. In recurrent high-grade glioma, extending the period during which disease remains stable can be meaningful even when conventional objective responses are uncommon.
The next analyses should clarify whether the apparent benefit is concentrated in particular patients. NeOnc Technologies Holdings is continuing prespecified analyses separating Grade III from Grade IV disease and examining pharmacokinetics and quality of life. The company also plans to present the complete Phase 2a dataset, including more detailed safety information, at a future medical meeting.
Those subgroup results could materially influence trial design. Combining Grade III and Grade IV tumors creates a heterogeneous population with potentially different natural histories, making it important to determine whether the survival signal is broadly consistent or disproportionately driven by one group.
Intranasal delivery is NEO100’s central differentiation in the fight against the blood-brain barrier
NEO100 is a pharmaceutical-grade formulation of perillyl alcohol administered through a nasal mask and nebulizer. The treatment is designed to move along olfactory and trigeminal pathways and reach the brain without depending on conventional systemic drug delivery across the blood-brain barrier.
The blood-brain barrier remains one of the fundamental obstacles in brain cancer drug development because it limits the concentration many therapeutics can achieve inside central nervous system tumors. NeOnc Technologies Holdings is attempting to address that challenge through the route of administration itself rather than solely modifying the molecular structure of the drug.
The home-based treatment model could eventually provide another point of differentiation. Patients in NEO100-01 administered the medicine four times daily outside an infusion center, potentially reducing the logistical burden associated with intravenous cancer therapies. Four-times-daily dosing is still substantial, however, and future studies will need to examine long-term adherence and quality of life alongside efficacy.
Safety appeared manageable in the topline dataset. NeOnc Technologies Holdings reported no major toxicities across the 24-patient cohort and said adverse events were predominantly low grade, consistent with earlier Phase 1 observations in which no severe or dose-limiting toxicities were identified. Several patients have remained on daily intranasal treatment for more than a year.
The small dataset again limits certainty. Uncommon adverse events may only emerge after significantly more patients are exposed, while extended treatment in a registrational study will provide a clearer picture of chronic nasal, neurological and systemic tolerability.
FDA discussions now matter more as NeOnc’s limited cash position raises execution risk
NeOnc Technologies Holdings intends to request a Type B meeting with the FDA to discuss the most efficient registrational development path. The agency’s response could determine the size, design and cost of the next NEO100 study and whether the company can leverage the Phase 2a dataset within a later registration package.
Financing is particularly relevant because NeOnc Technologies Holdings reported only about $2 million in cash and cash equivalents at June 30. The company also maintained an undrawn $10 million related-party line of credit and had approximately $44.5 million potentially available under an equity purchase facility, subject to its terms and trading-volume limitations. It additionally maintains an at-the-market program and a $300 million shelf registration statement.
Research and development expenses increased to $2.6 million during the second quarter from $0.7 million a year earlier as the company expanded clinical sites, manufacturing, recruitment and NEO100 analysis work. NeOnc Technologies Holdings posted a quarterly net loss of $14.2 million, although approximately $5.7 million of operating expenses represented noncash stock-based compensation. Net cash used in operating activities totaled roughly $11.8 million during the first six months of 2026.
The balance sheet means favorable FDA feedback alone may not be enough to move NEO100 rapidly into a larger registrational trial. Additional equity financing, credit usage or another strategic source of capital may be required, particularly if regulators request a sizable randomized study. That conclusion is an inference based on the reported liquidity and development stage.
Investor reaction has also been notably cautious. NeOnc Technologies Holdings shares were trading near $3.57 in early afternoon trading on August 12, down about 17.9% from the previous close despite the positive headline result, after ranging between approximately $3.46 and $5.24. The company’s market capitalization stood near $88 million.
The decline suggests investors may be focusing on the uncontrolled trial design, the discrepancy between the strong survival endpoint and relatively low objective response rate, financing requirements and uncertainty over what the FDA will demand next. That interpretation is an inference from the trading pattern rather than a confirmed explanation from market participants.
NEO100 has nevertheless cleared an important clinical hurdle. A 48.9% six-month progression-free survival estimate and 26.09-month median overall survival in heavily pretreated IDH1-mutant high-grade glioma are strong enough to justify a larger test. The next step is proving that the result survives prospective comparison in a study designed to support approval, while NeOnc Technologies Holdings secures enough capital to reach that point.
